Sanford-Burnham Medical
Research Institute
Science Daily
May 16, 2013
Summary:
The scientists at Sanford-Burnham Medical Research Institute have been
studying the hardening of the arteries. They particularly focused on a
destructive protein called Dkk1. Their studies suggest that the
development of drug therapies to inhibit Dkk1 signaling may help limit
arteriosclerotic disease. This would be helpful for diseases such
as chronic renal deficiency or diabetes. In chronic renal deficiency and
diabetes, unregulated Dkk1 signaling can be destructive, so restraining the
action of Dkk1 for a prolonged period of time may be helpful.
When Dkk1
is working normally, it is essential for wound repair. However, inflammatory
responses inside artery walls triggered by hyperglycemia and other metabolic
injuries, can trigger prolonged and destructive Dkk1 signaling. Dkk1
causes the conversion of endothelial cells, cells that line the interior
surface of artery walls, into mesenchymal cells. It directs connective tissue
formation; the process is called endothelial-mesenchymal transition. The
fibrosis inside artery walls that results from this causes a dangerous
hardening of arteries that increases blood pressure and ultimately impairs
blood flow.
Drug
therapy will target specifically where Dkk1 must be inhibited, the arteries.
Researchers hope to develop a therapeutic drug that would include a Dkk1
inhibitor and a peptide engineered to target specific vascular tissues. The
scientists will continue to research the prevention of artery hardening.
Connection:
This article relates to our
study of human body systems because we studied the circulatory systems. The
hardening of the arteries is often associated with the disease that we studied,
arteriosclerosis. Arteriosclerosis is an advanced stage of plaque buildup in
the arteries. The deposits on the artery wall harden. With arteriosclerosis,
the arteries lose their ability to stretch. This disease increases blood
pressure and the chance for blood clots to form within blood vessels.
How can the inflammatory response triggered by hyperglycemia and other metabolic injuries trigger prolonged and destructive Dkk1 signaling?
ReplyDeleteSince the function of Dkk1 is wound repair, Dkk1 would be triggered to aid inflammation. This inflammation can be caused by hyperglycemia.
Deletehttp://www.sciencedaily.com/releases/2013/05/130516161700.htm
Are there any negative consequences of inhibiting Dkk1 production?
ReplyDeleteScientists are trying to develop a therapeutic drug that will specifically target the malfunctioning Dkk1 (the Dkk1 in the arteries). There would be negative consequences for inhibiting ALL Dkk1 because there is healthy Dkk1 regulating cartilage and joint remodeling. However, scientists are trying to devise a method to only inhibit malfunctioning Dkk1 in the arteries.
Deletehttp://www.sciencedaily.com/releases/2013/05/130516161700.htm
This comment has been removed by the author.
ReplyDelete